Oppenheimer & Co’s AnaptysBio ANAB Stock Holding History

Oppenheimer & Co’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,526	Closed	-$479K	–	1380
2023 Q2	$479K	Buy	+23,526	New	+$477K	0.01%	994

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Oppenheimer & Co's ANAB Position: Q3 2023 in Review

Oppenheimer & Co sold out of AnaptysBio (ANAB) in Q3 2023, closing a stake of 23,526 shares — an estimated $479K sold.

Oppenheimer & Co first reported a position in ANAB in Q2 2023 and held it in 1 quarter. The position peaked at $479K in Q2 2023. 116 funds tracked by Wall St. Rank hold ANAB as of Q3 2023.

Oppenheimer & Co reported no remaining AnaptysBio position as of Q3 2023 after selling out during the quarter.
Oppenheimer & Co sold 23,526 AnaptysBio shares in Q3 2023, an estimated $479K.
Oppenheimer & Co first reported a position in AnaptysBio in Q2 2023 and held it in 1 quarter.
Oppenheimer & Co's AnaptysBio position peaked at $479K in Q2 2023.
116 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2023.

Based on Oppenheimer & Co's 13F filing for Q3 2023, filed 8 Nov 2023.